Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

10-1-2021

Evaluation of patient-reported delays and affordability-related
barriers to care in head and neck cancer
Nicholas R Lenze
University of North Carolina at Chapel Hill

Jeannette T Bensen
University of North Carolina at Chapel Hill

Laura Farnan
University of North Carolina at Chapel Hill

Siddharth Sheth
University of North Carolina at Chapel Hill

Jose P Zevallos
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Lenze, Nicholas R; Bensen, Jeannette T; Farnan, Laura; Sheth, Siddharth; Zevallos, Jose P; Yarbrough,
Wendell G; and Zanation, Adam M, "Evaluation of patient-reported delays and affordability-related barriers
to care in head and neck cancer." OTO Open. 5, 4. 2473974X211065358 (2021).
https://digitalcommons.wustl.edu/oa_4/170

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Nicholas R Lenze, Jeannette T Bensen, Laura Farnan, Siddharth Sheth, Jose P Zevallos, Wendell G
Yarbrough, and Adam M Zanation

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/170

Original Research

Evaluation of Patient-Reported Delays
and Affordability-Related Barriers
to Care in Head and Neck Cancer

OTO Open
2021, Vol. 5(4) 1–9
Ó The Authors 2021
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2473974X211065358
http://oto-open.org

Nicholas R. Lenze, MD, MPH1,2 , Jeannette T. Bensen, MS, PhD3,
Laura Farnan, PhD4, Siddharth Sheth, DO, MPH5,
Jose P. Zevallos, MD, MPH6, Wendell G. Yarbrough, MD, MMHC1,4,7,
and Adam M. Zanation, MD1
Abstract

Keywords

Objective. To examine the prevalence and predictors of
patient-reported barriers to care among survivors of head
and neck squamous cell carcinoma and the association with
health-related quality of life (HRQOL) outcomes.

health services accessibility, head and neck neoplasms,
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Study Design. Retrospective cohort study.
Setting. Outpatient oncology clinic at an academic tertiary care
center.
Methods. Data were obtained from the UNC Health Registry/
Cancer Survivorship Cohort. Barriers to care included selfreported delays in care and inability to obtain needed care
due to cost. HRQOL was measured with validated questionnaires: general (PROMIS) and cancer specific (FACT-GP).
Results. The sample included 202 patients with head and
neck squamous cell carcinoma with a mean age of 59.6
years (SD, 10.0). Eighty-two percent were male and 87%
were White. Sixty-two patients (31%) reported at least 1
barrier to care. Significant predictors of a barrier to care in
unadjusted analysis included age 60 years (P = .007),
female sex (P = .020), being unmarried (P = .016), being
uninsured (P = .047), and Medicaid insurance (P = .022).
Patients reporting barriers to care had significantly worse
physical and mental HRQOL on the PROMIS questionnaires
(P \ .001 and P = .002, respectively) and lower cancerspecific HRQOL on the FACT-GP questionnaire (P \ .001),
which persisted across physical, social, emotional, and functional domains. There was no difference in 5-year OS
(75.3% vs 84.1%, P = .177) or 5-year CSS (81.6% vs 85.4%,
P = .542) in patients with and without barriers to care.
Conclusion. Delay- and affordability-related barriers are
common among survivors of head and neck cancer and
appear to be associated with significantly worse HRQOL
outcomes. Certain sociodemographic groups appear to be
more at risk of patient-reported barriers to care.

H

ead and neck squamous cell carcinoma (HNSCC)
contributes to a significant burden of disease in the
United States with an estimated 65,410 new cases
and 14,620 deaths in 2019.1,2 Despite advancements in
treatment, there has been relatively little improvement in
oncologic outcomes for patients with HNSCC over the
past few decades.3,4 Achieving optimal outcomes for patients
with HNSCC relies on timely diagnosis, treatment, and
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posttreatment surveillance.5 This can be especially challenging in patients with head and neck cancer because these
patients on average have lower socioeconomic status when
compared with patients who have other types of cancer6 and
therefore may face many barriers across the continuum of
cancer care.
Although there is evidence to suggest that delays in diagnosis, treatment initiation, and time to postoperative radiation
are associated with worse survival in HNSCC, there is limited
insight into subjective patient-reported barriers to care that
may drive these findings. In one study that conducted qualitative interviews of 24 patients with HNSCC, Carroll et al identified several patient-reported barriers, such as transportation,
perceived cost, and failure to recognize initial symptoms as a
problem.7 In a study that used patient and provider interviews
to assess barriers to timely postoperative radiation therapy in
HNSCC, Graboyes et al identified inadequate patient education, postsurgical sequelae, insufficient coordination during
care transitions, fragmentation of care across organizations,
and patient travel burden as important contributors.8
A better understanding of patient-reported barriers to care
in HNSCC can help identify new targets for intervention
aimed at improving oncologic and patient-reported outcomes
in this population. To help address this gap in literature, we
assessed patient-reported barriers to care among an institutional cohort of patients with HNSCC. We examined the relationship between demographic, social, and clinical variables
and reported barriers to care. We also examined associations
of barriers to care with health-related quality of life (HRQOL)
and survival outcomes.

Materials
This study was approved by the Institutional Review Board at
the University of North Carolina (UNC) at Chapel Hill. All
subjects provided consent to participate in this study.

Study Design and Sample Selection
We performed a retrospective cross-sectional analysis of
patients with head and neck cancer identified through the
UNC Health Registry/Cancer Survivorship Cohort (HR/
CSC). The HR/CSC is a cohort of patients who presented to
UNC oncology outpatient clinics at the North Carolina
Cancer Hospital between May 2012 through July 2016. In this
sample, 144 (71.3%) cases were incident (enrolled before
treatment initiation), and 58 (28.7%) cases were prevalent
(enrolled anytime during or after treatment). The mean
follow-up was 5.5 years (SD, 2.30) after initial diagnosis.
Patients were eligible to participate in the HR/CSC if they
were at least 18 years of age and had English or Spanish language proficiency. Patients meeting these eligibility criteria
were approached by research staff in the oncology clinic and,
upon informed consent, were enrolled in the HR/CSC.
Of the eligible patients with HNSCC approached in clinic
for enrollment, 64% consented to participate. When compared
with patients who consented to participate, those who were
approached but declined to participate were older (mean
[SD], 65.2 [11.0] vs 59.2 [12.5] years; P = .007) and more
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likely to have advanced-stage cancer (III/IV; 81.2% vs
59.1%, P = .002); there was no significant difference in sex
(36.1% vs 34.0% female, P = .808) or race (18.5% vs 13.9%
Black, P = .525) between those who consented and declined
to participate. Patients completed the study questionnaires at a
median number of 27 days after enrollment via a computerassisted telephone interview. Patients from the HR/CSC were
included in this analysis if they had a pathologically confirmed diagnosis of HNSCC.

Questionnaires and Data Extraction
Information on demographics, socioeconomic status, medical
history, and barriers to care was obtained via a baseline questionnaire. Barriers to care were elicited through 2 questions:
‘‘Have you delayed getting care for any of the following reasons in the past year?’’ and ‘‘During the past year, was there
any time when you needed any of the following but didn’t get
it because you couldn’t afford it?’’ A full listing of response
options is provided in Supplement A (available online). For
this analysis, patients were considered to have a barrier to
care if they responded ‘‘yes’’ to at least 1 option in question 1
or 2. Questions and response options in Supplement A were
derived from the 2010 National Health Interview Survey section on adult access to health care and utilization9 and the
Carolina Head and Neck Cancer Epidemiology Study.10 In
addition to the literature that informed the creation of these 2
surveys, there is evidence supporting the specific patientreported barriers queried in our study across a variety of
cancer types.11-16
Clinical data were extracted from patient medical records,
including tumor site, American Joint Committee on Cancer
stage (seventh edition), and p16 tumor status. HRQOL outcomes
were measured with the PROMIS questionnaire (PatientReported Outcomes Measurement Information System)17 and
the FACT-GP questionnaire (Functional Assessment of Cancer
Therapy–General Population),18 which is divided into physical,
social, emotional, and functional domains.

Statistical Analysis
We used descriptive statistics to examine the sociodemographic and clinical characteristics of patients with and without barriers to care. Bivariate testing methods included the 2sided t test, chi-square test, and Fisher’s exact test (for \5
expected observations). We next used univariable and multivariable logistic regression models to estimate significant predictors of having a barrier to care. In addition, we performed a
stratified analysis examining delay- and affordability-related
barriers separately. Multicollinearity was assessed with variance inflation factor testing. Number of treatment modalities
was omitted from the multivariable model due to collinearity
with treatment types. We also performed a sensitivity analysis
to determine if incident vs prevalent case status (proxy for
time between diagnosis and enrollment) had any impact on
our primary outcome of patient-reported barriers to care.
We used simple and multiple linear regression models
to examine the relationship of barriers to care with HRQOL.
For the PROMIS scales, we used T scores normalized to
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population means. We next constructed Kaplan-Meier curves
to assess 5-year overall survival (OS) and cancer-specific survival (CSS) in patients with and without barriers to care. We
used the log-rank test to compare the survival curves and
obtain P values. We used unadjusted and adjusted Cox proportional hazards models to obtain hazard ratio (HR) and 95%
CI estimates for 5-year survival outcomes with respect to barriers to care. The proportional hazards assumption was
assessed through Schoenfeld residuals and was met for all
variables. Updates on patient vital status were provided
monthly up until October 1, 2020, by the North Carolina
Department of Health and Human Services. Vital status and
cause of death were known for all subjects at 5 years of
follow-up from initial diagnosis.
The multivariable logistic regression, multiple linear
regression, and adjusted Cox proportional hazards models all
adjusted for the following: age, sex, race, marital status, education, insurance status, employment status, distance to hospital, history of tobacco use, history of alcohol use, comorbid
depression, comorbid anxiety, tumor site, overall stage, and
treatment type. We used a statistical significance criterion of
P \ .05 for all testing. Adjustment for multiplicity was not
performed because this study was strictly exploratory; therefore, any significant results should be interpreted as exploratory and warrant confirmation in additional studies.19 We
used Stata 16.0 (StataCorp LP) for all analyses.

Results
The sample included 202 patients with HNSCC with a mean
age of 59.6 years (SD, 10.0). Patients completed the study
questionnaires on average 13.8 months (range, 6 days–255
months) after initial diagnosis. Eighty-two percent of patients
were male and 87% were White. The majority of patients had
private insurance or Medicare (88%), and 70% had advancedstage cancer (III/IV) at diagnosis. Baseline characteristics are
summarized, stratified by patients with and without barriers to
care (Table 1).

Patient-Reported Barriers to Care
In total, 62 patients (31%) cited at least 1 barrier to care: 33
patients, a delay-related barrier (Supplement A, question 1);
13 patients, an affordability-related barrier (Supplement A,
question 2); and 16 patients, a delay- and affordability-related
barrier.
Because of a 3-way tie by number of responses (n = 10),
the top 3 most frequently reported delay-related barriers actually became the 5 most frequently reported: ‘‘You couldn’t
get an appointment soon enough’’ (n = 22), ‘‘The clinic or
doctor’s office wasn’t open when you got there’’ (n = 13),
‘‘You couldn’t get through on the telephone’’ (n = 10), ‘‘You
did not have health insurance’’ (n = 10), and ‘‘You did not
have the money you needed to pay expenses’’ (n = 10). The 3
most frequently reported affordability-related barriers were
‘‘dental care, including check-ups’’ (n = 18), ‘‘doctor’s visit’’
(n = 9), and ‘‘over-the-counter medicine’’ (n = 9).
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Table 1. Baseline Characteristics.a
Patients reporting barriers
to care, No. (%)

Age, y, mean (SD)
Sex
Male
Female
Race
White
Non-White
Marital status
Married
Not married
Education
High school or less
College graduate
Postgraduate/
professional degree
Insurance
Private
Uninsured
Medicare
Medicaid
Currently work for pay
Distance to hospital,
miles, mean (SD)
History
Tobacco use
Alcohol use
Comorbid
Depression
Anxiety
Tumor site
Oral cavity
Oropharynxb
Hypopharynx
Larynx
Other
Overall stage: AJCC (7th ed)
Early: I/II
Advanced: III/IV
Treatment
Surgery alone
Surgery 1 adjuvant RT
Surgery 1 adjuvant CRT
RT or chemotherapy alone
CRT
No. of treatment modalities
1
2
3

Yes
(n = 62)

No
(n = 140)

57.0 (9.2)

60.8 (10.2)

P value
.012
.018

45 (72.6)
17 (27.4)

121 (86.4)
19 (13.6)

50 (80.7)
12 (19.3)

126 (90.0)
14 (10.0)

35 (57.4)
26 (42.6)

103 (74.6)
35 (25.4)

44 (73.3)
11 (18.3)
5 (8.3)

80 (58.0)
33 (23.9)
25 (18.1)

31 (50.0)
5 (8.1)
17 (27.4)
9 (14.5)
27 (44.3)
72.8 (71.6)

84 (60.0)
3 (2.1)
46 (32.9)
7 (5.0)
68 (49.3)
69.0 (57.6)

.514
.706

40 (64.5)
32 (51.6)

81 (61.4)
67 (47.9)

.673
.622

16 (25.8)
17 (27.4)

13 (9.6)
17 (12.5)

.003
.010
.890

21 (33.9)
29 (46.8)
2 (3.2)
7 (11.3)
3 (4.8)

53 (37.9)
67 (47.9)
4 (2.9)
10 (7.1)
6 (4.3)

18 (30.5)
41 (69.5)

38 (29.2)
92 (70.8)

21 (33.9)
7 (11.3)
11 (17.7)
6 (9.7)
17 (27.4)

37 (26.6)
18 (13.0)
37 (26.6)
10 (7.2)
37 (26.6)

27 (43.6)
24 (38.7)
11 (17.7)

45 (32.9)
55 (40.1)
37 (27.0)

.067

.015

.091

.022

.859

.621

.235

Abbreviations: CRT, chemoradiation therapy; RT, radiation therapy.
a
Bold indicates P \.05.
b
p16 status was available for 35 patients with oropharyngeal squamous cell
carcinoma.
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Table 2. Univariable Logistic Regression Model for Predictors of Barriers to Care.a
Any barrier

Age 60 vs .60 y
Female sex
Non-White race vs White
Not married vs married
Education vs college graduate
High school or less
Postgraduate/professional degree
Insurance vs private
Uninsured
Medicare
Medicaid
Currently work for pay
Distance to hospital .52 miles (median)
History
Tobacco use
Alcohol use
Comorbid
Depression
Anxiety
Tumor site vs oral cavity
Oropharynx
Hypopharynx
Larynx
Other
Advanced stage vs early
Treatment vs surgery alone
Surgery 1 adjuvant RT
Surgery 1 adjuvant CRT
RT or chemotherapy alone
CRT
No. of treatment modalities vs 1
2
3

Delay barrier

Affordability barrier

OR (95% CI)

P value

OR (95% CI)

P value

OR (95% CI)

P value

2.35 (1.27-4.37)
2.41 (1.15-5.03)
2.16 (0.93-4.99)
2.19 (1.16-4.13)

.007
.020
.072
.016

2.29 (1.17-4.47)
2.04 (0.94-4.43)
2.20 (0.92-5.22)
1.63 (0.83-3.20)

.015
.071
.075
.157

1.77 (0.79-3.98)
1.58 (0.62-4.04)
1.10 (0.35-3.46)
3.14 (1.39-7.09)

.164
.340
.873
.006

1.65 (0.76-3.58)
0.60 (0.18-1.95)

.205
.396

1.23 (0.55-2.77)
0.68 (0.21-2.24)

.612
.526

5.04 (1.14-22.29)
0.72 (0.06-8.36)

.033
.796

4.52 (1.02-20.03)
1.00 (0.50-2.00)
3.48 (1.19-10.16)
0.82 (0.45-1.50)
1.05 (0.56-1.97)

.047
.997
.022
.514
.881

5.71 (1.28-25.48)
0.89 (0.42-1.89)
1.56 (0.50-4.88)
0.77 (0.40-1.48)
1.11 (0.56-2.17)

.023
.761
.449
.431
.764

1.35 (0.15-12.01)
1.78 (0.71-4.47)
7.35 (2.30-23.62)
0.67 (0.30-1.51)
0.60 (0.26-1.41)

.787
.217
.001
.336
.241

1.14 (0.61-2.14)
1.16 (0.64-2.11)

.673
.622

0.94 (0.48-1.82)
1.38 (0.72-2.63)

.848
.328

1.71 (0.71-4.08)
0.70 (0.31-1.55)

.230
.376

3.29 (1.47-7.37)
2.64 (1.24-5.62)

.004
.012

3.00 (1.32-6.81)
3.02 (1.39-6.55)

.009
.005

3.35 (1.34-8.37)
2.10 (0.84-5.23)

.010
.113

1.09 (0.56-2.13)
1.26 (0.21-7.42)
1.77 (0.59-5.26)
1.26 (0.29-5.12)
0.94 (0.48-1.84)

.795
.797
.306
.757
.859

1.06 (0.52-2.16)
0.67 (0.07-6.14)
1.83 (0.60-5.68)
0.96 (0.18-5.05)
0.83 (0.41-1.70)

.881
.724
.296
.960
.611

1.19 (0.50-2.81)
1.28 (0.14-12.12)
0.85 (0.17-4.31)
0.80 (0.09-7.10)
0.72 (0.32-1.68)

.700
.830
.848
.841
.446

0.69 (0.25-1.91)
0.52 (0.22-1.24)
1.06 (0.34-3.32)
0.81 (0.37-1.78)

.469
.141
.924
.598

0.46 (0.14-1.54)
0.63 (0.26-1.56)
1.10 (0.33-3.64)
0.76 (0.33-1.77)

.207
.321
.881
.532

0.58 (0.15-2.30)
0.39 (0.12-1.31)
0.61 (0.12-3.09)
0.85 (0.32-2.26)

.441
.127
.550
.751

0.73 (0.37-1.43)
0.50 (0.22-1.13)

.356
.095

0.62 (0.30-1.30)
0.60 (0.25-1.41)

.207
.240

0.81 (0.34-1.92)
0.41 (0.31-1.35)

.636
.144

Abbreviations: CRT, chemoradiation therapy; OR, odds ratio; RT, radiation therapy.
a
Bold indicates P \.05.

Predictors of Patient-Reported Barriers to Care
In the univariable analysis, significant predictors of having a
barrier to care included age 60 years (odds ratio [OR],
2.35 [95% CI, 1.27-4.37]; P = .007), female sex (OR, 2.41
[95% CI, 1.15-5.03]; P = .020), being unmarried (OR, 2.19
[95% CI, 1.16-4.13]; P = .016), being uninsured (OR,
4.52 [95% CI, 1.02-20.03]; P = .047), and having Medicaid
(OR, 3.48 [95% CI, 1.19-10.16]; P = .022; Table 2, Figure 1).
Comorbid depression and anxiety were also significantly associated with having a barrier to care (P = .004 and P = .012,
respectively). In a sensitivity analysis, there was no difference
in prevalent/incident case status in patients with and without
barriers to care (27.4% vs 29.3% prevalent cases, P = .787).

In the stratified analysis, the associations for age 60
years (P = .015), having no insurance (P = .023), and
comorbid anxiety (P = .005) persisted only for delay-related
barriers (Table 2). The associations for being unmarried (P =
.006) and having Medicaid (P = .001) persisted just for
affordability-related barriers. Furthermore, education of high
school or less was associated with having an affordabilityrelated barrier (P = .033). A subset analysis was performed to
assess the association between p16-positive tumor status and
barriers to care among patients with oropharyngeal squamous
cell carcinoma (OPSCC). Among patients with available
tumor p16 status, there were 26 cases of p161 OPSCC and 9
cases of p16– OPSCC. There was no significant difference in
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Table 3. Multivariable Logistic Regression Model for Predictors of
Barriers to Care.a
Any barrierb

Figure 1. Forest plot displaying significant predictors of having a barrier to care based on the univariable logistic regression models.

the rate of p16 positivity in patients with and without barriers
to care (75.0% vs 73.9%, respectively; P . .999).
In the multivariable logistic regression model, age 60
years (OR, 3.65 [95% CI, 1.28-10.39]; P = .015) and treatment with surgery plus adjuvant chemoradiation (OR, 0.27
[95% CI, 0.08-0.99]; P = .048) remained the only significant
associations with having a barrier to care (Table 3).

HRQOL Outcomes
In the unadjusted model, patients citing a barrier to care had
significantly worse HRQOL on general (PROMIS) and
cancer-specific (FACT-GP) quality-of-life scales (Table 4).
Specifically, patients indicating a barrier to care had worse
physical HRQOL (mean difference [MD], 24.79 [95% CI,
27.41 to 22.17]; P \ .001) and mental HRQOL (MD, 24.14
[95% CI, 26.78 to 21.50]; P = .002) on the PROMIS scales.
On the FACT-GP scale, patients who had a barrier to care had
significantly worse HRQOL scores: physical (MD, 22.03
[95% CI, 23.52 to 20.55]; P = .008), social (MD, 22.02 [95%
CI, 23.68 to 20.35]; P = .018), emotional (MD, 22.18 [95%
CI, 23.54 to 20.81]; P = .002), and functional (MD, 22.61
[95% CI, 24.77 to 20.44]; P = .019). Having a barrier to care
was not significantly associated with any of the HRQOL scores
in the fully adjusted models.

Survival Outcomes
The mean time from diagnosis to last follow-up was 5.5 years
(SD, 2.30), and vital status at 5 years was known for all participants in this study. The 5-year OS rate for the cohort was
81.7%, and the 5-year CSS rate was 84.6%. There was no significant difference in 5-year OS (75.3% vs 84.1%; log-rank
P = .177) or CSS (81.6% vs 85.4%; log-rank P = .542) in
patients with and without barriers to care, respectively
(Figures 2 and 3).
In the unadjusted and adjusted Cox proportional hazard
models, there were no significant associations between

Age 60 vs .60 y
Female sex
Non-White race vs White
Not married vs married
Education vs college graduate
High school or less
Postgraduate/professional degree
Insurance vs private
Uninsured
Medicare
Medicaid
Currently work for pay
Distance to hospital
.52 miles (median)
History
Tobacco use
Alcohol use
Comorbid
Depression
Anxiety
Tumor site vs oral cavity
Oropharynx
Hypopharynx
Larynx
Other
Advanced stage vs early
Treatment vs surgery alone
Surgery 1 adjuvant RT
Surgery 1 adjuvant CRT
RT or chemotherapy alone
CRT

OR (95% CI)

P value

3.65 (1.28-10.39)
2.65 (0.89-7.88)
1.66 (0.51-5.36)
1.40 (0.57-3.44)

.015
.079
.397
.463

1.37 (0.48-3.90)
0.67 (0.16-2.77)

.550
.581

6.09 (0.97-38.38)
1.72 (0.56-5.26)
1.65 (0.34-8.04)
0.64 (0.25-1.66)
1.02 (0.46-2.26)

.054
.345
.537
.360
.965

0.98 (0.39-2.44)
1.14 (0.50-2.59)

.967
.750

1.77 (0.51-6.23)
2.62 (0.74-9.28)

.371
.136

1.41 (0.45-4.40)
1.45 (0.14-14.85)
0.86 (0.16-4.53)
1.94 (0.28-13.47)
1.85 (0.62-5.54)

.558
.755
.862
.504
.272

0.76 (0.17-3.40)
0.27 (0.08-0.99)
1.69 (0.32-9.05)
0.69 (0.20-2.47)

.723
.048
.538
.573

Abbreviations: CRT, chemoradiation therapy; OR, odds ratio; RT, radiation
therapy.
a
Bold indicates P \.05.
b
Adjusted for age, sex, race, marital status, education, insurance status,
employment status, distance to hospital, history of tobacco use, history of
alcohol use, comorbid depression, comorbid anxiety, tumor site, overall
stage, and treatment type.

barriers to care and either 5-year OS or CSS (Table 5). This
nonsignificant effect persisted even when stratifying by
patients who had a delay- and affordability-related barrier
(P = .438 for OS and P = .395 for CSS).

Discussion
In this study we used a cross-sectional institutional cohort of
HNSCC survivors to retrospectively assess patient-reported
barriers to care and their relationship with HRQOL and survival outcomes. The prevalence of patient-reported barriers to
care in our sample was 31%, which included delay- and
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Table 4. Relationship Between Barriers to Care and Health-Related Quality of Life.
Patients reporting barriers, mean (SD)
Survey: domain
FACT-GP
Total
Physical
Social
Emotional
Functional
PROMIS
Physical
Mental

Adjusteda

Unadjusted

Yes

No

MD (95% CI)

P value

MD (95% CI)

P value

75.3 (17.7)
21.3 (5.4)
19.6 (5.8)
18.0 (5.7)
16.4 (7.1)

84.1 (15.4)
23.4 (4.7)
21.6 (5.4)
20.2 (3.9)
19.0 (7.2)

28.83 (213.68 to 23.99)
22.03 (23.52 to 20.55)
22.02 (23.68 to 20.35)
22.18 (23.54 to 20.81)
22.61 (24.77 to 20.44)

\.001
.008
.018
.002
.019

24.50 (29.81 to 0.81)
21.35 (23.02 to 0.33)
20.67 (22.53 to 1.19)
21.27 (22.85 to 0.31)
21.21 (23.67 to 1.24)

.096
.114
.478
.115
.330

44.9 (8.5)
49.6 (9.3)

49.7 (8.8)
53.7 (8.5)

24.79 (27.41 to 22.17)
24.14 (26.78 to 21.50)

\.001
.002

22.89 (25.83 to 0.05)
21.04 (23.90 to 1.82)

.054
.472

Abbreviations: FACT-GP, Functional Assessment of Cancer Therapy–General Population; MD, mean difference; PROMIS, Patient-Reported Outcomes
Measurement Information System.
a
Adjusted for age, sex, race, marital status, education, insurance status, employment status, distance to hospital, history of tobacco use, history of alcohol
use, comorbid depression, comorbid anxiety, tumor site, overall stage, and treatment type.

Figure 2. Kaplan-Meier curves for overall survival in patients with
and without barriers to care.

Figure 3. Kaplan-Meier curves for cancer-specific survival in patients
with and without barriers to care.

affordability-related barriers. Younger (P = .007), female (P =
.020), unmarried (P = .016), uninsured (P = .047), and
Medicaid-insured (P = .022) patients were significantly more
likely to have a barrier to care in the unadjusted analysis.
Patients citing a barrier to care had significantly worse
HRQOL on general and cancer-specific questionnaires in the
unadjusted analysis, but there was no association with OS or
CSS at 5 years. The sociodemographic and HRQOL associations with barriers to care were mostly lost in the adjusted
models. Despite this, our exploratory study provides novel
insight into which patients may be at most risk for barriers to
care and can help inform future research.
Several studies in current literature have reported an association between low socioeconomic status and advanced stage
at presentation for HNSCC,20-23 which may be a proxy for
delays in cancer diagnosis. In our stratified analysis, indicators of low socioeconomic status, such as having no insurance,
Medicaid insurance, and education of high school or less,
were all associated with patient-reported barriers to care. Our
findings that younger age and unmarried status predict
patient-reported barriers to care may be explained by reduced
time or financial resources to obtain optimal care. Other studies have found an association between unmarried status and
delays in diagnosis of HNSCC.24,25 In a study assessing
delays in diagnosis of HPV-positive oropharyngeal cancer,
Karp et al noted that retired patients had a trend toward
quicker diagnosis (P = .05).26 Retired individuals may have
more time and savings to address important health issues,
which may explain our finding that younger age was associated with barriers to care. Finally, female sex was associated
with patient-reported barriers to care in our model but did not
reach statistical significance in the stratified analyses. This
finding could be secondary to known sex-based disparities in
income in the United States.27 More research is warranted to
confirm and uncover the drivers of this potential sex disparity.
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Table 5. Cox Proportional Hazards Models for 5-Year Mortality With Respect to Patient-Reported Barriers to Care.a
Adjustedb

Unadjusted

5-y OS
Any barrier
Delay only
Affordability only
Delay and affordability
5-y CSS
Any barrier
Delay only
Affordability only
Delay and affordability

HR (95% CI)

P value

HR (95% CI)

P value

1.57 (0.81-3.02)
1.59 (0.71-3.59)
1.54 (0.46-5.15)
1.53 (0.53-4.43)

.181
.257
.484
.438

2.34
1.91
2.45
1.91

(0.92-5.97)
(0.74-4.95)
(0.81-7.45)
(0.61-6.05)

.075
.182
.114
.269

1.26 (0.60-2.62)
1.53 (0.65-3.62)
1.68 (0.50-5.65)
0.42 (0.06-3.12)

.542
.332
.404
.395

2.48
1.82
1.48
3.48

(0.88-6.95)
(0.60-5.56)
(0.39-5.52)
(0.92-13.26)

.084
.290
.563
.067

Abbreviations: CSS, cancer-specific survival; HR, hazard ratio; OS, overall survival.
a
Reference variable is ‘‘no barriers’’ for all models.
b
Adjusted for age, sex, race, marital status, education, insurance status, employment status, distance to hospital, history of tobacco use, history of alcohol
use, comorbid depression, comorbid anxiety, tumor site, overall stage, and treatment type.

Interestingly, patient-reported barriers to care were not
associated with oncologic outcomes in our study, such as
cancer stage or survival. Some studies have found that objective delays in care correlate with worse overall survival in
HNSCC, such as time from diagnosis to treatment initiation,
time to postoperative radiation therapy, and total treatment
package time.5 This discrepancy may be secondary to our limited sample size or differences in patient characteristics
among studies. It is also possible that objective measures of
delayed care are more prognostic than subjective patientreported barriers to care. Despite the lack of association with
oncologic outcomes in our study, the high prevalence of
patient-reported barriers to care (31%) and association with
HRQOL outcomes warrant further consideration. Patientreported outcomes such as HRQOL are recognized as an
important but understudied area of head and neck cancer survivorship.28 A better understanding of HRQOL in head and
neck cancer can be used to guide interventions aimed at
improving patient satisfaction and value-based care.29,30
The findings from this study can be used as a foundation
for additional research and interventions aimed at addressing
barriers to care in head and neck cancer. The at-risk sociodemographic groups identified here may benefit from resources
such as social workers and financial navigators. Based on the
common delay- and affordability-related barriers indicated by
patients, clinics should work to optimize communication with
patients about follow-up appointments. This could involve
phone call or text reminders, which have been shown to
reduce no-show rates.31,32 Finally, systemic interventions that
help reduce the number of uninsured and underinsured
patients in the United States may help to address some of the
underlying issues leading to barriers in care.
Our study has several limitations. It is important to recognize that we did not measure barriers at the provider or system
level. These could include issues such as communication
among providers, documentation exchange, inadequate

knowledge about optimal care, time and resource constraints,
workforce shortages, and care coordination among health systems.33,34 On the patient level, we did not measure health literacy, which could plausibly influence barriers to care and
outcomes in head and neck cancer.35 Although our study
measured the mean patient distance to the hospital, it failed to
capture other geographic barriers, such as rurality and concentration of health care providers in certain areas. Finally, our
questionnaire provided patients with several options for barriers to care without the opportunity for free-text elaboration.
Ideally, future studies in this area will include mixed qualitative and quantitative components for a more complete
understanding.
The potential for selection bias in our study is high because
sampling relied on voluntary participation in an outpatient
oncology clinic. Patients who declined to participate were disproportionately older (P = .007) and had a more advanced
cancer stage (P = .002) than the patients who provided consent. Additionally, it is plausible that eligible patients facing
barriers to care may have been less likely to participate given
the time and effort involved. By nature of enrolling patients
who made it to their clinic appointments, our study systematically fails to include patients facing barriers that prevented
them from making it to clinic. Given these collective biases,
we expect that the prevalence of barriers to care is an underestimation of the true population statistic. Finally, our sample
was from a single large public outpatient clinic setting and
may not be generalizable to all patients with HNSCC in the
United States. Despite these limitations, our study provides
novel insight into patient-reported barriers to care in HNSCC.
Further research is needed to confirm these findings and identify ways to address barriers to care in head and neck cancer.

Conclusion
Patient-reported barriers to care affect nearly one-third of
patients with head and neck cancer and are associated with
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significantly worse quality-of-life outcomes. Young age,
female sex, unmarried status, no insurance, and Medicaid
insurance appear to be the strongest risk factors for patientreported barriers to care.
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